Thrombosis and aspirin 86 items
The antifibrinolytic side of apo(a): venous thromboembolism data and the aspirin signals in ASPREE and MESA, coronary and valvular.
Studies
- Lp(a) as a cardiovascular risk factor: the first EAS consensus panel (Nordestgaard et al., EHJ 2010)
- Oxidised phospholipids on Lp(a) drive arterial wall inflammation and a primed monocyte response (van der Valk et al., Circulation 2016)
- Lp(a) drives ASCVD, MI and aortic stenosis risk independent of C-reactive protein: Copenhagen (Thomas et al., EHJ 2023)
- Aspirin benefits older adults with Lp(a)-raising genotypes in primary prevention: ASPREE (Lacaze et al., JACC 2022)
- APOLLO: single ascending doses of SLN360 (zerlasiran) lower Lp(a) by up to 98 percent (Nissen et al., JAMA 2022)
- AHA scientific statement: Lp(a) is a genetically determined, causal and prevalent risk factor for ASCVD (Reyes-Soffer et al., ATVB 2022)
- Lp(a) lowering by alirocumab reduces total cardiovascular events independent of LDL-C: ODYSSEY OUTCOMES (Szarek et al., EHJ 2020)
- Lp(a) as a cause of cardiovascular disease: epidemiology, genetics and biology (Nordestgaard and Langsted, J Lipid Res 2016)
- Lp(a) and venous thromboembolism: a signal in premenopausal women and in postmenopausal MHT users, none in men (Ezzat et al., EHJ 2026)
- Regular aspirin use and lower incidence of aortic valve calcium and severe stenosis in people with high Lp(a): MESA (Razavi et al., EHJ 2026)
- Aspirin use and lower CHD events in people with Lp(a) above 50 mg/dL: MESA (Bhatia et al., JAHA 2024)
- Lp(a) as a pharmacological target: premises, promises and prospects (Greco et al., Circulation 2025)
- Lp(a) activates monocytes via TLR2 and NF-kB to drive tissue factor expression, the first mechanistic link between Lp(a) and immunothrombosis, systems-biology study finds (J Lipid Res 2025)
- Lp(a)'s heart attack risk is not explained by prothrombotic mechanisms, 410,177-person UK Biobank genetic study finds, and Lp(a) shows no link to venous thromboembolism at all (Eur J Intern Med 2025)
- Nature Reviews Cardiology essay revisits how Lp(a) affects platelets, and why the ASPREE trial found aspirin helped genetically high-Lp(a) individuals most (Nat Rev Cardiol 2024)
- In 16,150 Chinese coronary disease patients, the lowest Lp(a) quintile, not the highest, had the most bleeding at 2 years (Thromb Haemost 2024)
- Lp(a) genetically drives atherosclerotic narrowing but not venous blood clots, a Mendelian randomisation study of 41,231 people (Arterioscler Thromb Vasc Biol 2012)
- Lp(a) above 30 mg/dL doubles coronary disease risk in women, tripling when combined with high fibrinogen or CRP, the Nurses' Health Study of 32,826 women (Eur Heart J 2005)
- Elevated Lp(a) raises PAD prevalence (OR 1.81) and triples repeat revascularisation after limb procedures (J Vasc Surg 2026)
- Adding LAA morphology and Lp(a) to a thrombus-risk model beats CHA2DS2-VA in atrial fibrillation, cohort of 418 (Int J Cardiol Heart Vasc 2026)
- Lp(a) is procoagulant, not antifibrinolytic, in whole particle form, mechanistic clot study (J Thromb Haemost 2026)
- Lp(a)'s link to venous thromboembolism stays unsettled even as new agents cut Lp(a) by up to 98%, review by a KOL-heavy author group finds (Thromb Haemost 2025)
- Beyond oxidised phospholipids: diacylglycerols, a novel endothelial receptor and accelerated coagulation emerge as new Lp(a) cellular targets, Koschinsky group review finds (Curr Opin Lipidol 2025)
- Low Lp(a) aids clot dissolution but oxidised Lp(a) blocks it, a biphasic effect mechanistic study finds, explaining Lp(a)'s prothrombotic potential (J Lipid Atheroscler 2025)
- Pelacarsen does not alter platelet reactivity via thromboxane A2 or P2Y12 pathways in 275 patients on aspirin or dual antiplatelet therapy (J Thromb Thrombolysis 2023)
- High Lp(a) doubles coronary heart disease risk only in people with elevated Factor VIII or hs-CRP, an interaction found in 6,495 MESA participants (J Clin Lipidol 2023)
- Every 10 mg/dL rise in Lp(a) raises peripheral artery disease risk by 6%, a dose-response meta-analysis of 565,209 people across 68 studies (Eur J Med Res 2022)
- Lp(a) does not predict future venous thromboembolism risk, a Finnish cohort of 2180 men pooled with 66,583 participants across 5 studies (Scand Cardiovasc J 2019)
- Lipoprotein apheresis improves clot formation and fibrinolysis markers in refractory angina patients with high Lp(a), a randomised crossover trial of 20 patients (J Clin Lipidol 2019)
- Lp(a) is linked to a 56% higher risk of venous thromboembolism, though the effect is small, a meta-analysis of 14 studies and over 14,000 patients (Semin Thromb Hemost 2017)
- Mendelian randomisation applied to Lp(a) two decades ago proved causality for cardiovascular disease, aortic stenosis and diabetes, a review of Lp(a) genetics (Cardiovasc Drugs Ther 2016)
- Lp(a) above 300 mg/L more than doubles the risk of retinal vein occlusion, an Italian case-control study of 262 patients and 262 controls (Atherosclerosis 2010)
- Lp(a) predicts carotid stenosis and occlusion but not total plaque area, suggesting a thrombotic mechanism, a study of 876 patients (Arterioscler Thromb Vasc Biol 2008)
- Lp(a), not fibrinogen, independently predicts coronary plaque progression on serial imaging, a study of 60 left main coronary arteries (J Am Coll Cardiol 2006)
- Lp(a) above 450 mg/L predicts earlier restenosis after angioplasty, especially combined with anticardiolipin antibodies, a study of 167 patients (Atherosclerosis 2001)
- Lp(a) and homocysteine together raise coronary risk nearly 5-fold in women, but not men, a study of 750 men and 403 women (Arterioscler Thromb Vasc Biol 2000)
- Nephrotic syndrome flares triple Lp(a) binding to fibrin, revealing a competitive tug-of-war with plasminogen, a study of 61 children (Arterioscler Thromb Vasc Biol 2000)
- Elevated Lp(a) raises cardiovascular risk mainly when homocysteine is also high, coronary disease cohort of 530 (BMC Cardiovasc Disord 2026)
- Hyperacute-phase Lp(a) predicts intracoronary thrombus, stable-phase Lp(a) predicts layered plaque, OCT study of 142 (Coron Artery Dis 2026)
- Lp(a) drives atherosclerosis through endothelial injury, inflammation and impaired fibrinolysis, review (Eur Cardiol 2026)
- Elevated Lp(a) predicts mechanical prosthetic heart valve thrombosis, with a threshold above 19.6 mg/dL flagging risk (J Artif Organs 2025)
- The LPA +121 G>A variant protects against venous thromboembolism, but Lp(a) protein level itself does not predict it, case-control study finds (Biochem Biophys Rep 2025)
- Lp(a) and fibrinogen act synergistically on carotid plaque in 3,913 Chinese coronary artery disease patients (Eur J Med Res 2025)
- Combined elevation of Lp(a) and hs-CRP, not Lp(a) alone, raises platelet reactivity on clopidogrel in 6,615 PCI patients (Clin Appl Thromb Hemost 2024)
- Smaller apo(a) isoforms and denser fibrin networks link elevated Lp(a) to thromboembolism, a review of prothrombotic and antifibrinolytic mechanisms (Arch Med Sci 2024)
- Aspirin may benefit primary prevention specifically in people with genetically elevated Lp(a), based on subgroup analyses of the Women Health Study and ASPREE (Curr Opin Lipidol 2023)
- Elevated Lp(a) is linked to a roughly fourfold higher risk of ischaemic stroke and thrombosis in children, though screening guidelines remain inconsistent, a review (Curr Atheroscler Rep 2023)
- In Chinese populations, elevated Lp(a) is linked to post-PCI thrombosis, aortic stenosis, stroke and diabetes, a review of a distinctive risk profile (Int J Biol Macromol 2023)
- Lp(a) rises with thrombotic activity but falls with inflammation during COVID-19 hospitalisation, with no link to mortality, in 211 Danish patients (Atherosclerosis 2022)
- Severe aortic stenosis patients have 35% higher Lp(a) and more lysis-prone fibrin clots, linking Lp(a) to a prothrombotic phenotype in 138 patients (Atherosclerosis 2022)
- LPA shares up to 70% of its sequence with plasminogen, explaining Lp(a) triple threat of atherosclerosis, thrombosis and inflammation, a review (Biomolecules 2022)
- Lp(a) surges during COVID-19 hospitalisation and those with the biggest rise face a 3-fold higher risk of blood clots, a Dutch pilot study of 219 patients (Atherosclerosis 2022)
- Elevated Lp(a) more than doubles retinal vein occlusion risk, a meta-analysis of 17,688 people across 13 studies (TH Open 2021)
- The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism
- Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial
- Lp(a) above 200 mg/L raises cardiovascular risk through both atherogenic and thrombotic pathways, a review of Lp(a) molecular mechanisms (Prague Med Rep 2019)
- Lp(a) is higher in heart attacks that strike in the early morning, linking it to a circadian clotting surge, a study of 42 patients (Atherosclerosis 2001)
- Glycated Lp(a) worsens blood clot-dissolving capacity in vascular cells more than native Lp(a), a mechanistic study relevant to diabetes (Atherosclerosis 2000)
- Lp(a) doubles during normal pregnancy but is not further raised by pre-eclampsia, a Scottish study of 30 women (Atherosclerosis 2000)
- MBRACE subanalysis links Lp(a) to tensile clot strength and oxidized phospholipids (Arterioscler Thromb Vasc Biol 2026)
- Evidence supports direct and indirect prothrombotic roles of lipoprotein(a) in atherosclerosis and thrombosis (Curr Opin Lipidol 2026)
- Combining Lp(a) and severe calcification predicts limb events after endovascular therapy for PAD, 145-patient study (Heart Vessels 2026)
- Lipoprotein(a) and premature myocardial infarction: Mechanistic insights and implications for PCI-era residual risk
- Lp(a) and peripheral artery disease independently stiffen arteries in hypertension, 366-patient cohort (J Clin Hypertens Greenwich 2026)
- Elevated Lp(a) tracks with peripheral artery disease in MASLD, cross-sectional study of 468 (BMC Cardiovasc Disord 2026)
- Systematic review of 26 studies finds Mendelian randomisation but not observational data supports a causal role for Lp(a) in atrial fibrillation (Pol Arch Intern Med 2025)
- Review maps how Lp(a)'s proatherogenic and prothrombotic biology may drive atrial fibrillation, and which Lp(a)-lowering drugs also help (Int J Med Sci 2025)
- Narrative review ties Lp(a)'s pro-inflammatory and prothrombotic biology to higher peripheral arterial disease incidence and restenosis risk (Vasc Health Risk Manag 2025)
- Lp(a) does not correlate with thrombus burden on CT pulmonary angiography in 90 patients with acute pulmonary embolism (Sci Rep 2024)
- Elevated Lp(a) predicts left atrial thrombus or spontaneous echo contrast in 481 atrial fibrillation patients with low CHA2DS2-VASc scores (Lipids Health Dis 2024)
- An Lp(a) gene haplotype (rs10455872-rs3798220) is linked to higher inflammation and antifibrinolytic markers after myocardial infarction (Int J Mol Sci 2024)
- Could Lp(a) explain COVID-19 clotting complications? A Dutch-led team proposes IL-6-driven Lp(a) surges as a testable hypothesis (Curr Atheroscler Rep 2020)
- Lp(a) remains an underused target in athero-thrombosis management due to assay standardization challenges, a review of Lp(a) mechanisms and therapy (J Cell Physiol 2018)
- Whether Lp(a) directly causes thrombosis or acts only through atherosclerosis remains unresolved, a review of Lp(a) prothrombotic role (J Lipid Res 2016)
- Elevated Lp(a) and prothrombotic changes may drive cardiovascular risk even in early kidney disease, a review (World J Nephrol 2015)
- Lp(a) shows only a mild link to coagulation factor V, angiographic cohort of 383 (J Clin Lipidol 2026)
- A case of Lp(a) at 925 nmol/L with recurrent cardiovascular events and a confirmed hypercoagulable profile despite optimal therapy (Front Cardiovasc Med 2026)
- Case report: a 2-year-old with cerebral venous sinus thrombosis had both iron deficiency anaemia and high Lp(a) (Front Pediatr 2025)
- Case series: two young patients presented with spontaneous coronary dissection and thrombosis alongside high Lp(a), not atherosclerosis (J Clin Lipidol 2025)
- Case report: Lp(a) of 113 mg/dL behind recurrent deep vein thrombosis and cerebral venous sinus thrombosis across two pregnancies (Case Rep Neurol 2025)
- Case report: an 11-year-old girl's sudden retinal artery occlusion was linked to elevated Lp(a) and high factor VIII (Cureus 2024)
- A rare case links elevated Lp(a) to aortic thrombosis in a non-aneurysmal aorta for the first time, a case report (Vasc Endovascular Surg 2016)
- A 34-year-old man with Lp(a) of 212 mg/dL and stroke saw his level drop 15% with aspirin but not statins, a case report (J Clin Lipidol 2016)
- Lp(a) may drive livedoid vasculopathy through thrombosis, fibrinolysis inhibition and autoimmunity, a hypothesis review (Med Hypotheses 2015)
- Lipoprotein(a) and Cardiovascular Disease: From Genetic Risk Factor to Therapeutic Target
- Clinical value of Lipoprotein(a) combined with CatLet coronary score in predicting adverse events after emergency PCI for AMI patients